Abstract Details

Title Symptom Severity in Early-stage Relapsing Remitting Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-009

Objective The aim of this study was to evaluate symptom severity and its correlation with different patient-reported and clinician-rated measures.

Background Patients with early-stage relapsing remitting multiple sclerosis (RRMS) might experience a variety of symptoms since the start of the disease. Patient-reported measures that assess multiple domains can help clinicians when assessing these symptoms, while further supporting remote disease monitoring.

Design/Methods

A multicentre, non-interventional study was conducted. Adult patients with RRMS diagnosis, disease duration ≤3 years, and Expanded Disability Status Scale (EDSS) score between 0-5.5 were included. Multiple Sclerosis Walking Scale (MSWS-12), NeuroQoL Upper Extremity (NeuroQoL-UE), EDSS, Pain Visual Analogue Scale (VAS), Modified Fatigue Impact Scale (MFIS-5), Symbol Digit Modalities Test (SDMT), Hospital Anxiety and Depression Scale (HADS), and SymptoMScreen (SyMS) were used to assess gait, hand dexterity, spasticity, pain, fatigue, information processing speed, depression and anxiety, and symptom severity, respectively.

Outcome measures associations were analysed using bivariate linear regressions.

Results

A total of 189 patients were included (mean age: 36.1±9.4 years, 71.4% female, mean disease duration: 1.4±0.8 years). Median EDSS score was 1.0 (IQR=0.0-2.0). A proportion of 20.3% (38/187) of patients were receiving symptomatic treatment.

Symptom severity was low with a mean (SD) overall SyMS score of 12.0 (10.8). SyMS mean score was highest for fatigue 1.6 (1.4) and lowest for bladder control 0.7 (1.1). SyMS walking, hand function, spasticity, pain, fatigue, cognition, depression, and anxiety dimensions showed significant correlations with MSWS-12, NeuroQoL-UE, EDSS, VAS, MFIS-5, SDMT, HADS-depression, and HADS-anxiety, respectively (0.046, -0.174, 0.246, 0.022, 0.219, -0.021, 0.244, and 0.210; all p=0 but spasticity p=0.007).

Conclusions Patient-reported measures can enable early-stage RRMS patients to communicate symptom severity in multiple overt and less tangible key domains facilitating shared decision-making. SyMS is a short and easy-to-use questionnaire that can be useful to screen for specific symptoms referring the patient for more extensive testing when needed.

Authors/Disclosures
Tamara Castillo-Trivino, MD, MAS, FAAN (Donostia University Hospital) PRESENTER	Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol-Myers Squibb. The institution of Dr. Castillo-Trivino has received research support from Basque Government.
	No disclosure on file
Rocío Gómez, Other (Roche Farma S.A.)	Ms. Gómez has received personal compensation for serving as an employee of Roche Farma Spain, Medical Department.
	No disclosure on file
Jesus Manuel Martin Martinez	Jesus Manuel Martin Martinez has nothing to disclose.
Javier Sotoca Fernandez	Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Ana M. Alonso Torres, MD	Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Ana Belen Caminero Rodriguez, MD (C/ Fuentes Claras #1)	Dr. Caminero Rodriguez has nothing to disclose.
Laura Borrega Canelo	Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NOVARTIS. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Laura Borrega Canelo has received research support from BRISTOL.
Jose Luis Sanchez Menoyo, MD (Neurologia - Hospital Galdakao-Usansolo)	Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Francisco Barrero-Hernandez	No disclosure on file
Carmen Calles, MD (Grupo 7 Viajes)	Dr. Calles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi, Biogen, Roche, Teva, Novartis, Merck. Dr. Calles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Teva, Biogen, Roche, Novartis, Merck.
Luis Brieva Ruiz, MD (Hospital Arnau Vilanova)	Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for All comercial companies interested in Multiple Sclerosis. Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Al comercial companies in Multiple Sclerosis. The institution of Dr. Brieva Ruiz has received research support from Carlos III Institut. Madrid. Spain..
Rosario Blasco Quilez (Hospital Puerta De Hierro)	Rosario Blasco Quilez has nothing to disclose.
Julio Dotor Garcia-Soto	JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck, Biogen, Sanofi-Genzyme, Almirall, Teva, UCB, Novartis.
Maria Campo Amigo	Maria Campo Amigo has nothing to disclose.
Laura Navarro	Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen idec. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132)	Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
	No disclosure on file
Olga Carmona	Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NEURAXPHARME. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI. Olga Carmona has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for SANOFI. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NEURAXPHARM.
	No disclosure on file
	No disclosure on file
Mariona Hervas Pujol	Mariona Hervas Pujol has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Merk, Bayer, Biogen, Almirall.
Jorge Maurino	Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.

��ɫ��

��ɫ��